Overview

HS-IT101 Injection for Advanced NSCLC

Status:
NOT_YET_RECRUITING

Trial end date:
2027-08-30

Target enrollment:

Participant gender:

Summary

An Open-Label, Single-Arm Phase Ib Clinical Trial Evaluating the Safety, Tolerability, and Preliminary Efficacy of HS-IT101 Injection in Subjects with Advanced NSCLC.

Phase:

PHASE1

Details

Lead Sponsor:

Qingdao Sino-Cell Biomedicine Co., Ltd.

Treatments:

Cyclophosphamide
fludarabine
Interleukin-2